Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines
Authors: Cristina Fortuno; Jessica Mester; Tina Pesaran; Jeffrey N Weitzel; Jill S. Dolinsky; Amal Yussuf; Kelly McGoldrick; Judy E Garber; Sharon A Savage; Payal P Khincha; D Gareth Evans; Maria Isabel Achatz; Kim E Nichols; Kara N. Maxwell; Joshua D. Schiffman; Renata Sandoval; Paul A. James; Amanda B Spurdle
Collaborators: City of Hope; Dana Farber Cancer Institute; GeneDx; General University Hospital in Prague; Hospital Sirio-Libanes; Huntsman Cancer Institute; National Cancer Institute, Clinical Genetics Branch; Peter MacCallum Cancer Centre and Royal Melbourne Hospital; QIMR Berghofer Medical Research Institute; University of Manchester; University of Pennsylvania